⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
PRLD News
Prelude Therapeutics Incorporated
Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting
globenewswire.com
PRLD
Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting
globenewswire.com
PRLD
Form 8-K
sec.gov
PRLD
PreludeDx Announces Publication in Breast Cancer Research Validating AidaBreast™, the Only Multi-Omic Test to Predict Locoregional Recurrence Risk and Radiation Therapy Benefit in Early-Stage Invasive Breast Cancer
prnewswire.com
PRLD
Form 8-K
sec.gov
PRLD
Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026
globenewswire.com
PRLD
Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026
globenewswire.com
PRLD
The $71 Billion Cancer Shift: Why The FDA Is Speeding Up
globenewswire.com
PRLD
MRNA
IMNM
AUTL
ONCY
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor
globenewswire.com
PRLD
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
globenewswire.com
ONCY
IMNM
PRLD
CNTX
RLAY